PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder.
性状
Solid
IC50 & Target[1][2]
Traditional Cytotoxic Agents
体内研究(In Vivo)
PSMA-ALB-56 accumulates much faster in tumor tissues and is more efficiently cleared from the blood and background tissues, which results in excellent tumor-to-background contrast already 4 hours after injection. PSMA-ALB-56 increases median survival in mice. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
-20°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献
[1]. Umbricht CA, et al. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Mol Pharm. 2018;15(6):2297-2306.